ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Manuscript_ChemRxiv.pdf (2.38 MB)

AMPA GluA2 subunit competitive inhibitors for PICK1 PDZ domain: Pharmacophore-based virtual screening, molecular docking, molecular dynamic simulation, and ADME studies

preprint
revised on 06.06.2021, 15:52 and posted on 07.06.2021, 12:12 by Shravan B. Rathod, Pravin B. Prajapati, Ranjan Pal
PICK1 (protein interacting with C kinase-1) plays a key role in the regulation of intracellular trafficking of AMPA GluA2 subunit that is linked with synaptic plasticity. PICK1 is a scaffolding protein and binds numerous proteins through its PDZ domain. Research showed that synaptic plasticity is altered upon disrupting the GluA2-PDZ interactions. Inhibiting PDZ and GluA2 binding lead to beneficial effects in the cure of neurological diseases thus, preventing PDZ-GluA2 binding is thought to novel therapeutic target in such diseases. To target this, generally, peptides were synthesized and tested. Though small organic molecules have been targeted to prevent these interactions, the number of such molecules is inadequate. Thus, in this study, ten molecular libraries containing large numbers of molecules were screened against the PDZ domain using pharmacophore-based virtual screening to find the best hits for the PDZ domain. Molecular docking, molecular dynamic simulation, and ADME analyses revealed that Hit_III (MolPort-005-050-255) shows efficient binding and drug likeness for the PDZ domain. This study suggests that tested hit may have potency against the PDZ domain and can be considered effective to treat neurological disorders.

History

Email Address of Submitting Author

shravanathorizon93@gmail.com

Institution

Department of Chemistry, Smt. S. M. Panchal Science College, Talod, Gujarat

Country

India

ORCID For Submitting Author

0000-0002-1870-2508

Declaration of Conflict of Interest

There are no conflicts to declare.

Version Notes

In this updated version, additional molecular blind docking and ADME analyses are added.